Jump to content

20250179142. Fusion Protein (SUNSHINE LAKE PHARMA ., .)

From WikiPatents

FUSION PROTEIN OF GLP-1 AND GDF15 AND USE THEREOF

Abstract: a fusion protein of glp-1 and gdf15 and the use thereof. the fusion protein comprises a first polypeptide fragment, a second polypeptide fragment and a third polypeptide fragment which are sequentially connected from an amino terminal to a carboxyl terminal; and the three polypeptide fragments sequentially comprise a glp-1 polypeptide, an immunoglobulin fc region and a gdf15 active domain. the fusion protein provided has a glp-1 and gdf15 dual-target activity. the fusion protein as a whole has excellent physicochemical properties and stability, and the two target molecules of glp-1 and gdf15 have a good activity and pharmacokinetic balance, facilitating the exertion of a dual-target effect.

Inventor(s): Jiangyu YAN, Lin XIAO, Junnan ZENG, Qingwei GONG, Xiaoli CHENG, Xiaoying LIU, Wenjia LI

CPC Classification: C07K14/605 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250179142


Cookies help us deliver our services. By using our services, you agree to our use of cookies.